**Amendments to the Claims:**

Please amend the claims as follows:

Claims 1-28 (Cancelled)

Claim 29 (Currently amended): A compound of formula I:



(I)

wherein $R^1$ and $R^2$ independently represent

(i) -$C_{1-6}$ alkyl, -$C_{3-8}$ cycloalkyl or -$C_{1-3}$ alkyl$C_{3-8}$ cycloalkyl,

or such a group in which alkyl or cycloalkyl is substituted by one or more halogen, -CN, nitro, hydroxy or -O$C_{1-6}$alkyl groups;

(ii) -$(CH_2)_eAr^1$ or -$(CH_2)_eOAr^1$;

or $NR^1R^2$ together represent pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or azepinyl, or such a group fused to a benzene ring, optionally substituted by one or more -$(CO)_n(CH_2)_tAr^1$, -$(CO)_nC_{1-6}$ alkyl$Ar^1Ar^2$, -$(CO)_nC_{1-6}$alkyl, -$(CH_2)_rOH$, -$(CH_2)_rO(CH_2)_pOH$, -$(CH_2)_rOC_{1-6}$ alkyl, -$O(CH_2)_tAr^1$, -$(CH_2)_rSO_2Ar^1$, piperidin-1-yl, -$(CH_2)_tCONR^8R^9$, -$NR^{10}(CO)_n(CH_2)_tAr^1$, -$NR^{10}(CO)_nC_{1-3}$alkyl$C_{3-6}$ cycloalkyl, -$NR^{10}(CO)_nC_{1-6}$ alkyldi$C_{3-6}$ cycloalkyl, -$CONR^{10}(CH_2)_tAr^1$, halogen, -$NHSO_2C_{1-6}$alkyl, -$SO_2NR^{10}R^{11}$, -$SO_2C_{1-6}$ alkyl or -$SO_2Ar^2$ groups;

$R^3$ represents -$C_{1-6}$alkylNHC(=NH)$NH_2$, -$C_{2-6}$alkenylNHC(=NH)$NH_2$, -$C_{2-6}$alkynylNHC(=NH)$NH_2$, -$C_{1-6}$alkyl$NR^{14}R^{18}$, -$(CH_2)_hCONR^{14}R^{18}$, -$(CH_2)_hCOC_{1-6}$alkyl, -$(CH_2)_dCHNR^{18}CONR^{20}R^{21}$, -$(CH_2)_mNR^{18}CONR^{14}R^{18}$, -$(CH_2)_dNR^{18}Ar^3$, -$(CH_2)_dCONR^{18}Ar^3$, -$(CH_2)_hCOOR^{18}$, -$(CH_2)_cAr^3$, -$O(CH_2)_cAr^3$, -$(CH_2)_dCO(CH_2)_sAr^3$ or -$(CH_2)_dOAr^3$;

or $R^3$ represents -$(CH_2)_c$-2,4-imidazolidinedione, -$(CH_2)_c$(piperidin-4-yl), -$(CH_2)_c$(piperidin-3-yl), -$(CH_2)_c$(piperidin-2-yl), -$(CH_2)_c$(morpholin-3-yl) or -$(CH_2)_c$(morpholin-2-yl) optionally substituted on nitrogen by -$(CO)_fC_{1-6}$alkyl,

$-(CO)_f(CH_2)_cAr^2$ or $-C(=NH)NH_2$;

or $R^3$ represents $-(CH_2)_z$dibenzofuran optionally substituted by $-C_{1-6}$alkyl or halogen;

or $R^3$ represents $-(CH_2)_c$-thioxanthen-9-one;

$R^4$ represents hydrogen, $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl$C_{3-6}$ cycloalkyl, $-(CH_2)_qAr^2$, $-C_{1-4}$alkyl-X-$R^7$, $-C_{1-4}$alkyl $SO_2C_{1-4}$ alkyl, $-C_{1-6}$alkyl$NR^{12}R^{13}$ or $-C_{1-6}$ alkyl$NR^{12}COC_{1-6}$ alkyl;

$R^5$ represents hydrogen, or $R^4R^5$ together with the carbon to which they are attached form a $C_{5-7}$ cycloalkyl ring;

$R^6$ represents hydrogen or $-C_{1-6}$alkyl~~, or $R^6$ and $R^4$ together with the N and C atoms to which they are respectively attached form a pyrrolidine ring~~;

$R^7$ represents hydrogen, $-(CH_2)_wNR^{12}R^{13}$, $-(CH_2)_uAr^2$ or $-(CH_2)_wNR^{12}COC_{1-6}$ alkyl;

$R^8$, $R^9$, $R^{16}$ and $R^{17}$ independently represent hydrogen, $-C_{1-6}$alkyl, $-C_{3-6}$cycloalkyl, $-C_{1-3}$alkyl$C_{3-6}$ cycloalkyl, $-C_{2-6}$alkenyl or $NR^8R^9$ or $NR^{16}R^{17}$ together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or piperazinyl N-substituted by $-C_{1-6}$ alkyl, -COphenyl or $-SO_2$methyl;

$R^{10}$, $R^{11}$, $R^{12}$, $R^{13}$, $R^{15}$, $R^{18}$, $R^{20}$ and $R^{21}$ independently represent hydrogen or $-C_{1-6}$alkyl;

$R^{14}$, $R^{19}$ and $R^{22}$ independently represent hydrogen, $-C_{1-6}$alkyl, $-C_{3-6}$ cycloalkyl or $-(CH_2)_x Ar^4$ or $NR^{14}R^{18}$ or $NR^{15}R^{22}$ together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or N-$C_{1-6}$alkylpiperaziuyl;

$Ar^1$ represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, $-C_{1-6}$alkyl ~~$C_{1-6}$alkyl~~, hydroxy, $-OC_{1-6}$alkyl, $-CF_3$ ~~$CF_3$~~, nitro, $-Ar^2$ or $-OAr^2$ groups;

$Ar^2$ represents phenyl optionally substituted by one or more halogen, $-C_{1-6}$alkyl, hydroxy, $-OC_{1-6}$alkyl, $-CF_3$ or nitro groups;

$Ar^3$ represents phenyl, a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S, or such a group fused to a benzene ring, optionally substituted by one or more $-CO(CH_2)_gAr^4$, $-(CH_2)_yAr^4$, $-(CH_2)_yCOAr^4$, $-(CO)_aC_{1-6}$ alkyl, $-(CO)_aC_{2-6}$ alkenyl, $-(CO)_aC_{2-6}$ alkynyl, $-(CO)_aC_{3-8}$cycloalkyl, $-(CO)_aC_{1-6}$haloalkyl, halogen, $-COCH_2$ CN, $-(CH_2)_bNR^{16}R^{17}$, $-(CH_2)_b$ $NHC(=NH)NH_2$, $-CYNR^{16}(CO)_aR^{17}$, $-(CH_2)_bNR^{15}COR^{19}$, $-(CH_2)_bCONR^{15}R^{22}$, $-(CH_2)_bNR^{15}CONR^{15}R^{22}$, $-(CH_2)_bCONR^{15}(CH_2)_jNR^{15}R^{22}$, $-(CH_2)_bSO_2NR^{15}R^{22}$, $-(CH_2)_bSO_2NR^{15}COAr^2$, $-(CH_2)_bNR^{15}SO_2R^{19}$, $-SO_2R^{19}$, $-SOR^{19}$, $-(CH_2)_zOH$,

-$COOR^{15}$, -CHO, -$OC_{1-10}$alkyl, -$O(CH_2)_jNR^{15}R^{22}$, -$O(CH_2)_j$ NHC(=NH)$NH_2$, -$O(CH_2)_bCONR^{16}R^{17}$, -$O(CH_2)_kCOOR^{15}$, -$O(CH_2)_jOAr^2$, -$O(CH_2)_bAr^2$, 3-phenyl-2-pyrazolin-5-one or 4,5-dihydro-3(2H)-pyridazinone groups;

$Ar^4$ represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen, -$C_{1-6}$alkyl, hydroxy, -$OC_{1-6}$alkyl, -$CF_3$, nitro or -$CONH_2$ groups;

X and Y independently represent O or S;

a, f, k, s and n independently represent 0 or 1;

b, c, r, x, y and z independently represent an integer 0 to 2;

d, g and u independently represent 1 or 2;

e, h, q and w independently represent an integer 1 to 3;

j and p independently represent an integer 2 to 4;

m independently represents an integer 0 to 4;

t independently represents an integer 0 to 3;

~~and~~ or salts ~~and~~ or solvates thereof.

Claim 30 (Previously presented): A compound according to claim 29 wherein $R^4$ represents -$C_{1-6}$alkyl, $R^5$ represents hydrogen or $R^4R^5$, together with the carbon to which they are attached, forms a cyclohexyl ring, and $R^6$ represents hydrogen or methyl.

Claim 31 (Previously presented): A compound according to claim 30 wherein $R^4$ represents -$C_{1-6}$alkyl and $R^5$ and $R^6$ represent hydrogen.

Claim 32 (Previously presented): A compound according to claim 31 wherein $R^4$ represents -$CH_2CHMe_2$ and $R^5$ and $R^6$ represent hydrogen.

Claim 33 (Previously presented): A compound according to claim 29 wherein $NR^1R^2$ together represents piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or 1,2,3,4-tetrahydroisoquinoline optionally substituted by a -$(CO)_n(CH_2)_rAr^1$, -$(CO)_nC_{1-6}$alkyl, -$(CH_2)_tCONR^8R^9$, -$NR^{10}(CO)_n(CH_2)_rAr^1$, -$NR^{10}(CO)_nC_{1-3}$ alkyl$C_{3-6}$ cycloalkyl, -$NR^{10}(CO)_nC_{1-6}$ alkyldi$C_{3-6}$ cycloalkyl, -$(CH_2)_rOC_{1-6}$ alkyl, -$(CH_2)_rO(CH_2)_pOH$, piperidin-1-yl, -$(CH_2)_rOH$ or -$CONR^{10}(CH_2)_rAr^1$ group.

Claim 34 (Previously presented): A compound according to claim 33 wherein $NR^1R^2$ together represents morpholinyl or piperazinyl optionally N-substituted by $-(CO)_nC_{1-6}$ alkyl, piperazinyl N-substituted by $-(CO)_n(CH_2)_rAr^1$, piperidinyl substituted by $-NR^{10}(CO)_n(CH_2)_rAr^1$ or piperidinyl substituted by $-(CH_2)_tCONR^8R^9$.

Claim 35 (Previously presented): A compound according to claim 29 wherein $R^3$ represents $-(CH_2)_c$-2,4-imidazolidinedione-3-yl, $-(CH_2)_c$-thioxanthen-9-one-3-yl, $-(CH_2)_cAr^3$, $-O(CH_2)_cAr^3$, $-(CH_2)_dOAr^3$ or $-(CH_2)_z$dibenzofuran.

Claim 36 (Previously presented): A compound according to claim 35 wherein $R^3$ represents $-OCH_2Ar^3$, $-CH_2OAr^3$ or dibenzofuran.

Claim 37 (Previously presented): A compound according to claim 36 wherein $R^3$ represents $-CH_2OAr^3$.

Claim 38 (Currently amended): A compound according to claim 29 wherein $R^4$ and $R^5$ have the stereochemical orientation shown in formula (Ia):



(Ia)

Claim 39 (Currently amended): A compound <u>selected from the group consisting</u> of ~~formula (I) which is~~:

(2S)-2-[((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid;

(2S)-2-({(2S)-4-Methyl-2-[(2-{[3-(1-piperidinylcarbonyl)-2-naphthyl] oxy}acetyl)amino]pentanoyl}amino)-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy]phenyl}propanoic acid;

(2S)-3-{4-[({4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-{[(2S)-4-methyl-2-({2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl} amino)pentanoyl]amino}propanoic acid;

(2S)-2-{[(2S)-4-Methyl-2-({2-[4-(1-piperidinylcarbonyl)phenoxy] acetyl}amino)pentanoyl]amino}-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl} propanoic acid;

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-{[(2S)-4-methyl-2-({2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl}amino)pentanoyl] amino}propanoic acid;

(2S)-3-{4-[({4-[(2-Cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl) amino]propanoic acid;

(2S)-3-{4-[({4-[(2,2-Dicyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl) amino]propanoic acid;

(2S)-2-({(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;

(2S)-2-({(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy] phenyl}propanoic acid;

(2S)-2-[((2S)-2-{[2-(2-Iodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy] phenyl}propanoic acid;

(2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;

(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;

(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2,4-dichlorophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;

(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-[((2S)-4-Methyl-2-{[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino]-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-({(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;

(2S)-2-{[(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl]amino}-3-[4-({[4-(1-piperidinylcarbonyl)-1-piperidinyl]carbonyl} oxy)phenyl]propanoic acid;

(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-(4-{[(4-{[(4-fluorobenzyl)amino]carbonyl}-1-piperidinyl) carbonyl]oxy}phenyl)propanoic acid;

(2S)-2-[((2S)-2-{[2-(2,4-Dichlorophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;

(2S)-2-[((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;

(2S)-2-[((2S)-4-Methyl-2-{[2-(2-propylphenoxy)acetyl]amino} pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;

(2S)-2-{[(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl]amino}-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;

(2S)-2-[((2S)-2-{[(Benzyloxy)carbonyl]amino}-4-methylpentanoyl) amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;

(2S)-3-[4-({[4-(2-Furoyl)-1-piperazinyl]carbonyl}oxy)phenyl]-2-[((2S) -2-{[2-(2-iodophenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;

(2S)-2-[((2S)-2-{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;

(2S)-2-{[(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-methylpentanoyl]amino}-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;

(2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methylpentanoyl)amino]propanoic acid;

(2S)-2-[((2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-(4-{[(4-{[2-(4-chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)propanoic acid;

(2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-[((2S)-2-{[2-(2-iodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]propanoic acid;

(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-(4-{[(4-{[2-(4-chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)propanoic acid;

(2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino)propanoic acid;

(2S)-3-(4-{[(4-{[2-(4-Chlorophenyl)acetyl]amino}-1-piperidinyl) carbonyl]oxy}phenyl)-2-({(2S)-4-methyl-2-[(2-{[3-(1-piperidinylcarbonyl)-2-naphthyl]oxy}acetyl)amino]pentanoyl}amino)propanoic acid;

(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[({4-[(2-cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid;

(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[({4-[(2,2-dicyclohexylacetyl)amino]-1-piperidinyl} carbonyl)oxy]phenyl}propanoic acid;

(2S)-2-[((2S)-4-Methyl-2-{[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid;

(2S)-2-[((2S)-2-{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}propanoic acid;

(2S)-3-{4-[({4-[(2-Cyclohexylacetyl)amino]-1-piperidinyl}carbonyl) oxy]phenyl}-2-[((2S)-2-{[2-(2-cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]propanoic acid;

and salts and solvates thereof.

Claim 40 (Currently amended): A compound selected from the group consisting of ~~formula (I) which is~~:
(2S)-2-[((2S)-2-{[2-(2-Iodophenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-{[(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}propanoic acid;
(2S)-2-[((2S)-2-{[2-(2-Cyclohexylphenoxy)acetyl]amino}-4-methyl pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-{4-[({4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl) oxy] phenyl}propanoic acid;
(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-{[(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}propanoic acid;
(2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino)propanoic acid;
(2S)-2-{[(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl pentanoyl]amino}-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;
(2S)-2-({(2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl}amino)-3-[4-({[4-(2-furoyl)-1-piperazinyl]carbonyl}oxy)phenyl] propanoic acid;
(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid;
(2S)-3-(4-{[(4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino)propanoic acid;
and salts and solvates thereof.

Claim 41 (Currently amended): A compound selected from the group consisting of ~~formula (I) which is~~:

(2S)-3-(4-{[(4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid;
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-({(2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl}amino) propanoic acid;
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-{[(2S)-2-({2-[2-(tert-butyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino} propanoic acid;
(2S)-2-[((2S)-4-Methyl-2-{[2-(2-methylphenoxy)acetyl]amino} pentanoyl)amino]-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-2-{[2-(2-benzoylphenoxy)acetyl]amino}-4-methylpentanoyl)amino] propanoic acid;
(2S)-2-{[(2S)-2-({2-[4-(Aminocarbonyl)phenoxy]acetyl}amino)-4-methylpentanoyl]amino}-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy) phenyl]propanoic acid;
and salts and solvates thereof.

Claim 42 (Currently amended): ~~A compound of formula (I) which is:~~
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid or a salt or solvate thereof.

Claim 43 (Currently amended): A compound ~~of formula (I)~~ according to claim 42 which is:
(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid potassium salt or a solvate thereof.

Claim 44 (Previously presented): A pharmaceutical composition comprising a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.

Claim 45 (Previously presented): A pharmaceutical composition comprising a compound of formula (I) according to claim 29 or a physiologically acceptable salt or solvate thereof in combination ~~together~~ with a long acting $\beta_2$ adrenergic receptor agonist.

Claims 46 and 47 (Cancelled)

Claim 48 (Currently amended): A process for preparation of a compound ~~of formula (I) as defined in~~ according to claim 29 which comprises:

(a) hydrolyzing ~~hydrolysis of~~ a carboxylic acid ester of formula (II)



(II)

wherein $R^1$, $R^2$, $R^3$, $R^4$, $R^5$ and $R^6$ are as defined in claim29 and R is a group capable of forming a carboxylic acid ester; or

(b) deprotecting a compound according to claim 29 ~~of formula (I)~~ which is protected.

Claims 49-55 (Cancelled)

Claim 56 (New): A method of inhibiting eosinophil infiltration into the lungs of a patient comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.

Claim 57 (New): A method of antagonizing VLA-4 comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.